Overview

The Gene Technology Act 2000, enacted to regulate the handling, storage, and use of genetically modified organisms in Australia, was introduced to address potential risks to human health and the environment posed by genetically modified products. The Office of the Gene Technology Regulator, which operates under the Department of Health, is the enacting body responsible for overseeing compliance with the Act. The primary policy objective of the Act is to ensure that any activities involving genetically modified organisms are conducted with appropriate safeguards to protect public health and the environment. In the context of the recent trial proposed by The University of Queensland for a genetically modified vaccine aimed at preventing respiratory disease in horses, the Regulator is conducting a risk assessment and soliciting public feedback to ensure all potential hazards are adequately managed before approving the trial.

Scope and Application

The scope of C2025G00129 (Gazette) pertains to the proposed trial of a genetically modified (GM) vaccine for the prevention of respiratory disease in horses, specifically focusing on the regulatory framework governing such trials in Australia. The Act applies to The University of Queensland as the applicant and to the horses that will be involved in the trial, which is intended to be conducted under controlled conditions at the Queensland Animal Science Precinct. The legislation encompasses the assessment and management of risks associated with the trial, including the protection of human health and safety and the environment, as outlined in the Risk Assessment and Risk Management Plan (RARMP) prepared by the Office of the Gene Technology Regulator. This Act operates within the Commonwealth jurisdiction, extending its reach to any activities involving the trial of genetically modified organisms under the oversight of the Gene Technology Act 2000. The Act does not specify any exclusions or exemptions in the provided text, but it does invite public submissions on the matter, indicating a transparent and inclusive approach to decision-making. The application and implications of this legislation can be further refined through subordinate instruments that may be developed to address specific issues arising during the trial.

Key Provisions

The main operative sections of the legislation pertain to the trial of a genetically modified (GM) vaccine for horses, as outlined in section 1 of DIR 214. This section outlines the specific application by The University of Queensland to conduct a trial under controlled conditions at the Queensland Animal Science Precinct. The application involves up to 10 trial horses, and the Regulator has prepared a Risk Assessment and Risk Management Plan (RARMP) to evaluate the potential risks to human health and the environment. The legislation requires the Regulator to welcome written submissions from the public on this matter before making a decision on whether to issue the licence. The obligations imposed on the parties by this Act include the requirement for The University of Queensland to adhere strictly to the conditions outlined in the RARMP and to conduct the trial in a manner that minimises risks to human health and the environment. The Regulator is tasked with assessing the RARMP and any public submissions before deciding whether to issue the licence for the trial. The public is also obligated to submit their written comments on the proposed trial by the specified deadline of 28 April 2025. In terms of potential breaches and the associated consequences, the legislation does not explicitly detail specific offences or penalties within the gazetted notice. However, any failure to comply with the conditions of the trial licence or the provisions of the RARMP could lead to regulatory action by the Office of the Gene Technology Regulator. This may include revocation of the trial licence, imposition of fines, or other corrective measures to ensure compliance with health and environmental standards. The severity of penalties would depend on the nature and extent of the breach, and could be outlined in more detail in the final decision or subsequent regulatory communications.